Ravi K Amaravadi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5156769/publications.pdf

Version: 2024-02-01

115	26,213	18465	22147
papers	citations	62 h-index	113 g-index

119	119	119	38580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
2	Survival in BRAF V600â€“Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	13.9	1,955
3	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature, 2015, 520, 373-377.	13.7	1,955
4	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 2017, 545, 60-65.	13.7	1,280
5	Autophagy in malignant transformation and cancer progression. EMBO Journal, 2015, 34, 856-880.	3.5	1,012
6	Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. Journal of Clinical Investigation, 2007, 117, 326-336.	3.9	983
7	TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion. Nature, 2019, 571, 211-218.	13.7	934
8	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	13.5	830
9	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clinical Cancer Research, 2011, 17, 654-666.	3.2	789
10	Recent insights into the function of autophagy in cancer. Genes and Development, 2016, 30, 1913-1930.	2.7	641
11	Autophagy in major human diseases. EMBO Journal, 2021, 40, e108863.	3.5	615
12	Targeting Autophagy in Cancer: Recent Advances and Future Directions. Cancer Discovery, 2019, 9, 1167-1181.	7.7	579
13	Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. Immunity, 2020, 52, 825-841.e8.	6.6	497
14	Targeting autophagy in cancer. Cancer, 2018, 124, 3307-3318.	2.0	484
15	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine, 2019, 25, 454-461.	15.2	466
16	A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy, 2014, 10, 1359-1368.	4.3	441
17	The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment. Clinical Cancer Research, 2007, 13, 7271-7279.	3.2	417
18	Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2013, 31, 3205-3211.	0.8	395

#	Article	IF	Citations
19	Combined MTOR and autophagy inhibition. Autophagy, 2014, 10, 1391-1402.	4.3	366
20	The survival kinases Akt and Pim as potential pharmacological targets. Journal of Clinical Investigation, 2005, 115, 2618-2624.	3.9	356
21	Targeting ER stressâ€“induced autophagy overcomes BRAF inhibitor resistance in melanoma. Journal of Clinical Investigation, 2014, 124, 1406-1417.	3.9	352
22	Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8253-8258.	3.3	348
23	Combined autophagy and proteasome inhibition. Autophagy, 2014, 10, 1380-1390.	4.3	310
24	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy, 2014, 10, 1369-1379.	4.3	309
25	Targeting Autophagy in Cancer: Update on Clinical Trials and Novel Inhibitors. International Journal of Molecular Sciences, 2017, 18, 1279.	1.8	293
26	Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research, 2012, 18, 370-379.	3.2	264
27	Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 2018, 24, 5347-5356.	3.2	253
28	Combined autophagy and HDAC inhibition. Autophagy, 2014, 10, 1403-1414.	4.3	240
29	SIRT1 is downregulated by autophagy in senescence and ageing. Nature Cell Biology, 2020, 22, 1170-1179.	4.6	236
30	Targeting the lysosome in cancer. Annals of the New York Academy of Sciences, 2016, 1371, 45-54.	1.8	221
31	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nature Communications, 2017, 8, 15916.	5.8	214
32	Measurements of Tumor Cell Autophagy Predict Invasiveness, Resistance to Chemotherapy, and Survival in Melanoma. Clinical Cancer Research, 2011, 17, 3478-3489.	3.2	213
33	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	7.7	197
34	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nature Communications, 2021, 12, 2349.	5.8	194
35	Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy. Clinical Cancer Research, 2013, 19, 2995-3007.	3.2	179
36	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 2021, 181, 195.	2.6	168

#	Article	IF	Citations
37	PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer. Cancer Discovery, 2019, 9, 220-229.	7.7	164
38	Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves antiâ€“PD-1/PD-L1 immunotherapy. Science Advances, 2020, 6, eaax7881.	4.7	164
39	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer Discovery, 2017, 7, 1266-1283.	7.7	159
40	ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression. Nature Cell Biology, 2019, 21, 889-899.	4.6	157
41	Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy, 2014, 10, 1415-1425.	4.3	149
42	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
43	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
44	Regulation of autophagy by canonical and non-canonical ER stress responses. Seminars in Cancer Biology, 2020, 66, 116-128.	4.3	120
45	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
46	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 2015, 21, 1652-1664.	3.2	106
47	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clinical Cancer Research, 2009, 15, 7711-7718.	3.2	104
48	Identification of secreted proteins that reflect autophagy dynamics within tumor cells. Autophagy, 2015, 11, 60-74.	4.3	101
49	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. Leukemia, 2019, 33, 981-994.	3.3	99
50	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Reports, 2020, 33, 108571.	2.9	99
51	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research, 2013, 19, 1784-1794.	3.2	98
52	A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics, 2015, 14, 2569-2575.	1.9	98
53	Targeting the unfolded protein response in cancer. Pharmacological Research, 2017, 120, 258-266.	3.1	93
54	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 2080-2087.	3.2	93

#	Article	IF	Citations
55	Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. OncoImmunology, 2018, 7, e1468956.	2.1	88
56	Lys05. Autophagy, 2012, 8, 1383-1384.	4.3	87
57	Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity, 2014, 41, 579-591.	6.6	87
58	Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib. American Journal of Ophthalmology, 2014, 158, 831-837.e2.	1.7	81
59	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. Journal of the National Cancer Institute, 2021, 113, 162-170.	3.0	81
60	Coâ€targeting <scp>BET</scp> and <scp>MEK</scp> as salvage therapy for <scp>MAPK</scp> and checkpoint inhibitorâ€resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	3.3	79
61	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
62	ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discovery, 2019, 9, 396-415.	7.7	71
63	Lysosomal Biology in Cancer. Methods in Molecular Biology, 2017, 1594, 293-308.	0.4	68
64	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer, 2015, 51, 1435-1443.	1.3	61
65	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 TÂcells. Cell Reports, 2021, 35, 109120.	2.9	60
66	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagyâ€mediated drug resistance in ovarian cancer cells, xenografts, and patientâ€derived xenograft models. Cancer, 2020, 126, 894-907.	2.0	54
67	Autophagy: a targetable linchpin of cancer cell metabolism. Trends in Endocrinology and Metabolism, 2013, 24, 209-217.	3.1	53
68	Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. Molecular Cancer Research, 2017, 15, 250-258.	1.5	52
69	Autophagy-induced tumor dormancy in ovarian cancer. Journal of Clinical Investigation, 2008, 118, 3837-40.	3.9	52
70	Lysosomes Support the Degradation, Signaling, and Mitochondrial MetabolismÂNecessary for Human Epidermal Differentiation. Journal of Investigative Dermatology, 2018, 138, 1945-1954.	0.3	48
71	Human epigenetic and transcriptional TÂcell differentiation atlas for identifying functional TÂcell-specific enhancers. Immunity, 2022, 55, 557-574.e7.	6.6	47
72	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	4.5	45

#	Article	IF	Citations
73	PPT1 inhibition enhances the antitumor activity of antiâ€“PD-1 antibody in melanoma. JCI Insight, 2020, 5, .	2.3	44
74	Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma. Radiology, 2017, 283, 702-710.	3.6	43
75	ICAM-1-mediated adhesion is a prerequisite for exosome-induced TÂcell suppression. Developmental Cell, 2022, 57, 329-343.e7.	3.1	42
76	Methods for Studying Autophagy Within the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2016, 899, 145-166.	0.8	38
77	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research, 2016, 76, 2720-2730.	0.4	33
78	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma. Clinical Cancer Research, 2022, 28, 1098-1106.	3.2	32
79	A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600â€“Mutant Solid Tumors. Clinical Cancer Research, 2018, 24, 22-32.	3.2	30
80	Autophagy in Tumor Immunity. Science, 2011, 334, 1501-1502.	6.0	29
81	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	3.2	29
82	Mouse Models Address Key Concerns Regarding Autophagy Inhibition in Cancer Therapy. Cancer Discovery, 2014, 4, 873-875.	7.7	28
83	FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA. Retina, 2019, 39, 502-513.	1.0	27
84	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	1.5	25
85	ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells. Autophagy, 2017, 13, 2056-2071.	4.3	23
86	Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Molecular Carcinogenesis, 2016, 55, 1526-1541.	1.3	20
87	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. Oncologist, 2016, 21, 84-94.	1.9	20
88	Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells. Molecular and Cellular Oncology, 2018, 5, e1395504.	0.3	18
89	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clinical Cancer Research, 2015, 21, 5215-5221.	3.2	17
90	Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation. Cancer Research, 2017, 77, 2869-2880.	0.4	17

#	Article	IF	Citations
91	Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. Haematologica, 2017, 102, e261-e265.	1.7	17
92	A Potent Autophagy Inhibitor (Lys05) Enhances the Impact of Ionizing Radiation on Human Lung Cancer Cells H1299. International Journal of Molecular Sciences, 2019, 20, 5881.	1.8	17
93	Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3545-3545.	0.8	16
94	Autophagy can contribute to cell death when combining targeted therapy. Cancer Biology and Therapy, 2009, 8, 2097-2100.	1.5	13
95	Dichotomous and stable gamma delta T-cell number and function in healthy individuals. , 2021, 9, e002274.		13
96	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. Annals of Surgical Oncology, 2020, 27, 2915-2926.	0.7	11
97	Autophagy and tumor cell invasion. Cell Cycle, 2012, 11, 3718-3718.	1.3	10
98	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. Annals of Surgical Oncology, 2019, 26, 4621-4630.	0.7	10
99	Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget, 2017, 8, 115140-115152.	0.8	9
100	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.4	9
101	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncology, 2018, 4, 126.	3.4	8
102	Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer. International Journal of Molecular Sciences, 2021, 22, 12402.	1.8	8
103	Transcriptional regulation of autophagy in RAS-driven cancers. Journal of Clinical Investigation, 2015, 125, 1393-1395.	3.9	7
104	Clinical trial results show promise of targeting autophagy BRAF mutant melanoma. Autophagy, 2022, 18, 1470-1471.	4.3	7
105	PUMA: A Puzzle Piece in Chloroquineâ€™s Antimelanoma Activity. Journal of Investigative Dermatology, 2013, 133, 2133-2135.	0.3	6
106	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology, 2019, 46, 190-194.	0.7	6
107	Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer. Oncologist, 2022, 27, 716-e689.	1.9	5
108	Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role?. Cancer Discovery, 2018, 8, 266-268.	7.7	3

#	Article	IF	Citations
109	Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist, 2022, 27, 799-808.	1.9	3
110	Anticancer properties of bisaminoquinolines with modified linkers. Bioorganic and Medicinal Chemistry Letters, 2021, 49, 128272.	1.0	2
111	Chloroquine Inhibits Autophagy, Enhances p53-Dependent Apoptosis, and Delays Tumor Recurrence in a Mouse Model of B Cell Lymphoma.. Blood, 2005, 106, 2421-2421.	0.6	2
112	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer and Prostatic Diseases, 2021, 24, 448-456.	2.0	0
113	A Case of Tumor-Induced Osteomalacia: Finding the Culprit Acetabular Tumor and Successful Resection with a Novel Hip Joint-Preserving Surgery. Journal of Orthopaedic Case Reports, 2021, 11, 37-41.	0.1	0
114	Discovery and Characterization of Small Molecule Inhibitors of Autophagy for Cancer Therapy.. Blood, 2006, 108, 2606-2606.	0.6	0
115	The Role of Autophagy in Drug Resistance and Potential for Therapeutic Targeting. , 2013, , 87-116.		0